
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
Find out how the NanoFlowSizer’s THALIA system is capable of measuring particle size in continuous liposome manufacturing with low lipid concentrations, below 3 mg/mL.






